戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 re effective than the pentavalent antimonial sodium stibogluconate (70 mg/kg) for the treatment of VL
2 e phosphatase (PTPase) assays, we found that sodium stibogluconate, a drug used in treatment of leish
3  the antileishmanial T cell repertoire where sodium stibogluconate alone had no effect.
4 o, approximately 58-fold more effective than sodium stibogluconate, and increased mouse splenic-pLck-
5 ntified and the sensitivity of L donovani to sodium stibogluconate assessed at each passage.
6 ly, pharmacological inhibition of SHP-1 with sodium stibogluconate augmented the function of all engi
7 B/c mice with imipramine in combination with sodium stibogluconate cleared organ Sb(R)LD parasites an
8 ably, pharmacologic inhibition of SHP-1 with sodium stibogluconate counteracted CD20 mAb-induced NK h
9 f SHP-2 and PTP1B required 100 micrograms/ml sodium stibogluconate, demonstrating differential sensit
10 term treatment with the antileishmanial drug sodium stibogluconate failed to significantly alter the
11 ork study, 110 patients with VL treated with sodium stibogluconate, failure rate was 59%.
12 sages, isolated parasites were refractory to sodium stibogluconate in in-vitro drug sensitivity assay
13 fective as the standard antileishmanial drug sodium stibogluconate in treatment of cutaneous leishman
14 , the cure rate of antimonial compounds (eg, sodium stibogluconate) in the treatment of visceral leis
15                                              Sodium stibogluconate inhibited 99% of SHP-1 activity at
16 These data represent the first evidence that sodium stibogluconate inhibits PTPases and augments cyto
17 d when treated with the antileishmanial drug sodium stibogluconate, <10% of mice were cured when the
18 ted IL-13(-/-) mice also responded poorly to sodium stibogluconate-mediated chemotherapy compared wit
19 tavalent state as a complex in drugs such as sodium stibogluconate (Pentostam) and meglumine antimona
20 c dose of miltefosine (14 days), or 20 mg/kg sodium stibogluconate plus 15 mg/kg paromomycin (17 days
21 n plus miltefosine (PM/MF) is noninferior to sodium stibogluconate plus paromomycin (SSG/PM) for trea
22 SHP-1 enzymatic activity via the cancer drug sodium stibogluconate potently augmented Treg suppressor
23                  In this study, we show that sodium stibogluconate (SSG) and IFN-alpha synergized to
24                        Based on finding that sodium stibogluconate (SSG) inhibited SHP-1, the anti-RC
25 ent antimony-carbohydrate complexes, such as sodium stibogluconate (SSG), has been reported to prolon
26               Pentavalent antimonials (e.g., sodium stibogluconate [SSG]) remain first-line drugs for
27 tion and the activity of the SHP-1 inhibitor sodium stibogluconate that induced IFN-gamma(+) cells fo
28                                              Sodium stibogluconate was offered to 11 patients in the